Extracellular granzyme K enhances PD-L1 transcription and stability via F2RL1 activation to facilitate tumor immune evasion in lung adenocarcinoma
Journal for ImmunoTherapy of Cancer · 2026
DOI: 10.1136/jitc-2025-013170 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2026. Verfasst von Hai-Ming Feng und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China. Hauptthemen laut MEDLINE: Granzymes, B7-H1 Antigen, Lung Neoplasms, Adenocarcinoma of Lung. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Gansu Province Science and Technology Program China (Youth Science and Technology Fund.
Abstract (Originalsprache)
Background
Granzyme K (GZMK) is a serine protease known for its perforin-dependent cytotoxicity. However, the non-cytotoxic role of GZMK in lung adenocarcinoma (LUAD) remains largely elusive.
Methods
Multiomics datasets were integrated to investigate the clinical relevance of GZMK and its association with programmed death-ligand 1 (PD-L1) in LUAD. Recombinant human GZMK (rhGzmK) was applied in tumor-CD8 + T cell co-culture systems, with its effects on PD-L1 expression and CD8 + T-cell function evaluated via flow cytometry. Key signaling proteins were analyzed by Western blotting. To evaluate the therapeutic potential of GZMK inhibition, a selective GZMK inhibitor was combined with anti-programmed cell death protein 1 (anti-PD-1) therapy in both C57BL/6 and human peripheral blood mononuclear cells (huPBMC)-reconstituted NVSG humanized mouse models. Finally, multiplex immunofluorescence analysis was conducted on paired pretreatment and post-treatment specimens from a clinical cohort of patients with LUAD receiving immunotherapy to assess the spatial dynamics of GZMK expression in response to treatment.
Results
GZMK upregulated PD-L1 expression on tumor cells and enhanced PD-L1/PD-1 binding. Furthermore, GZMK promoted CD8 + T-cell dysfunction through the induction of apoptosis, the promotion of CD8 + T-cell exhaustion and suppression of proliferation. Mechanistically, cleavage of F2R-like trypsin receptor 1 (F2RL1) by GZMK activated the AKT Serine/Threonine Kinase (AKT) /glycogen synthase kinase-3β/β-catenin and Janus kinase 2/signal transducer and activator of transcription 1 (JAK2/STAT1) pathways, triggering nuclear accumulation of β-catenin and phosphorylated STAT1, which ultimately drove PD-L1 transcription. Additionally, F2RL1 signaling upregulated COPS8, stabilizing PD-L1 through inhibition of its ubiquitin-mediated degradation. In vivo, pharmacological inhibition of GZMK synergized with anti-PD-1 therapy to suppress tumor growth and enhance CD8 + T-cell infiltration and function. Clinically, high baseline GZMK expression correlated with an improved response to immunotherapy, and anti-PD-1 treatment modulated the spatial distribution of GZMK within the tumor microenvironment.
Conclusion
In the absence of perforin, GZMK acquires an immunosuppressive function through F2RL1 activation on tumor cells, which in turn promotes the formation of an immune-suppressive niche. Accordingly, combined targeting of the GZMK/F2RL1 axis and the PD-1/PD-L1 pathway represents a promising synergistic strategy to overcome immune evasion in LUAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
- Gansu Province Key Laboratory of Environmental Oncology, Lanzhou, China.
- Cuiying Biomedical Research Center, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
- Department of Radiotherapy, Gansu Provincial People's Hospital, Lanzhou, China.
- Department of Thoracic Surgery, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China leebin@lzu.edu.cn.
- Department of Pulmonary and Critical Care Medicine, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Förderung
- Gansu Province Science and Technology Program China (Youth Science and Technology Fund
Zitieren
APA
Feng, H. M., Zhao, Y., Zhai, K. R., Li, B., Song, T. N., Meng, Y. Q., Huang, H. R., Li, Z., Cui, B. Q., Yang, N., & Su, Z. P. (2026). Extracellular granzyme K enhances PD-L1 transcription and stability via F2RL1 activation to facilitate tumor immune evasion in lung adenocarcinoma. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-013170
Vancouver
Feng HM, Zhao Y, Zhai KR, Li B, Song TN, Meng YQ, et al. Extracellular granzyme K enhances PD-L1 transcription and stability via F2RL1 activation to facilitate tumor immune evasion in lung adenocarcinoma. Journal for ImmunoTherapy of Cancer. 2026. doi:10.1136/jitc-2025-013170
BibTeX
@article{Feng2026,
author = {Feng, Hai-Ming and Zhao, Ye and Zhai, Ke-Rong and Li, Bin and Song, Tie-Niu and Meng, Yu-Qi and Huang, Hui-Rong and Li, Zheng and Cui, Bai-Qiang and Yang, Ning and Su, Zhi-Peng},
title = {Extracellular granzyme K enhances PD-L1 transcription and stability via F2RL1 activation to facilitate tumor immune evasion in lung adenocarcinoma},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
doi = {10.1136/jitc-2025-013170}
}
EUVIMED